HAWTHORNE, N.Y., Sept. 25 (UPI) -- U.S. firm Acorda Therapeutics said Monday it has seen positive results from a phase 3 study of Fampridine-SR for multiple sclerosis.
The company said that the study showed a significantly greater proportion of people taking the new treatment had a consistent improvement in walking speed and that the effect was maintained through the 14-week study period.
Researchers noted an average increase in walking speed compared to baseline of 25.2 percent for patients taking Fampridine, versus 4.7 percent for subjects receiving placebo, Acorda said.
The company added that the improvement in walking speed -- measured by the Timed 25-Foot Walk -- was observed in patients with all four of the major types of MS.
Acorda said it would request to meet with the Food and Drug Administration regarding the next steps in developing Fampridine for market.
